Published in J Korean Med Sci on July 03, 2013
Transglutaminase is a tumor cell and cancer stem cell survival factor. Mol Carcinog (2015) 0.84
Transglutaminase 2 in cancer. Am J Cancer Res (2015) 0.79
Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family. ScientificWorldJournal (2014) 0.78
Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway. Oncotarget (2016) 0.75
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. Cell Death Dis (2017) 0.75
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients. Oncotarget (2017) 0.75
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat (2011) 4.21
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol (2012) 4.15
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol (2008) 3.27
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene (2003) 2.96
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene (2000) 1.57
Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem (2004) 1.50
Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene (2011) 1.44
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs (2006) 1.39
Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem (2004) 1.39
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One (2010) 1.36
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res (2006) 1.36
Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol (2010) 1.33
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer (2013) 1.31
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res (1999) 1.22
Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell (2002) 1.18
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol (2009) 1.13
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg (2004) 1.00
Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. Mol Cancer (2011) 0.94
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2012) 0.90
The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sci (2000) 0.86
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer. Mol Cancer (2011) 0.85
Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol (2009) 0.83
Hydrogen peroxide mediates doxorubicin-induced transglutaminase 2 expression in PC-14 human lung cancer cell line. Exp Mol Med (1999) 0.78
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol (2007) 3.70
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol (2003) 2.08
Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. Ann Thorac Surg (2011) 1.80
Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg (2011) 1.69
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
Pulmonary inflammatory pseudotumor--a report of 28 cases. Korean J Intern Med (2002) 1.66
Prognostic value of visceral pleura invasion in non-small cell lung cancer. Eur J Cardiothorac Surg (2003) 1.65
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol (2005) 1.64
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
Clinical outcomes and prognosis of recurrent thymoma management. J Thorac Oncol (2012) 1.54
The role of surgical treatment in second primary lung cancer. Ann Thorac Surg (2011) 1.53
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer (2007) 1.49
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med (2012) 1.48
T-stage of non-small cell lung cancer directly invading an adjacent lobe. Eur J Cardiothorac Surg (2012) 1.46
Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg (2008) 1.46
Use of contrast enhancement and high-resolution 3D black-blood MRI to identify inflammation in atherosclerosis. JACC Cardiovasc Imaging (2010) 1.43
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Support Care Cancer (2013) 1.42
Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol (2008) 1.42
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res (2012) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Transcervical intraluminal repair of posterior membranous tracheal laceration through semi-lateral transverse tracheotomy. J Thorac Cardiovasc Surg (2007) 1.37
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res (2006) 1.36
Questionable role of interferon-γ assays for smear-negative pulmonary TB in immunocompromised patients. J Infect (2011) 1.33
Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem (2004) 1.32
Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis. BMC Infect Dis (2011) 1.30
Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scand J Infect Dis (2012) 1.28
Surgical treatment of tuberculous cold abscess of the chest wall. Yonsei Med J (2002) 1.27
Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (2007) 1.26
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med (2011) 1.26
Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J (2012) 1.20
Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis (2010) 1.20
Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg (2004) 1.20
Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis (2010) 1.17
Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J (2012) 1.16
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther (2012) 1.16
Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg (2009) 1.15
Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med (2011) 1.14
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol (2009) 1.13
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res (2006) 1.12
Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet (2011) 1.12
Basaloid carcinoma of the lung: a really dismal histologic variant? Ann Thorac Surg (2003) 1.11
Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol (2009) 1.11
High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res (2009) 1.10
Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest (2003) 1.08
Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer (2007) 1.05
The clinical utility of polymerase chain reaction for the diagnosis of pleural tuberculosis. Clin Infect Dis (2005) 1.04
Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol (2009) 1.03
Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer (2011) 1.02
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J Neuropathol Exp Neurol (2005) 1.00
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J (2013) 0.99
A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer (2010) 0.99
Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg (2013) 0.99
Thoracoscopic esophagectomy for esophageal cancer: feasibility and safety of robotic assistance in the prone position. J Thorac Cardiovasc Surg (2009) 0.98
Crystal structure of human transglutaminase 2 in complex with adenosine triphosphate. Int J Biol Macromol (2010) 0.98
TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci U S A (2011) 0.98
Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Ther (2013) 0.98
Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis (2009) 0.98
Bilateral video-assisted thoracoscopic thymectomy has a surgical extent similar to that of transsternal extended thymectomy with more favorable early surgical outcomes for myasthenia gravis patients. Surg Endosc (2010) 0.98
Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer (2013) 0.98
Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry (2005) 0.98
Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J (2012) 0.98
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2009) 0.97
MMP expression profiling in recurred stage IB lung cancer. Oncogene (2004) 0.97
Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis (2011) 0.96